GSK-2556286

• CAT Number: I028347
• CAS Number: 1210456-20-4
• Molecular Formula: C18H23N3O3
• Molecular Weight: 329.40
• Purity: 98%
• Synonyms: GSK-2556286; GSK 2556286; GSK2556286; GSK 286; GSK286; GSK-286
• Target: Bacterial
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Store at -20°C
• IUPAC Name: 6-[[4-(2,3-dimethylphenoxy)piperidin-1-yl]methyl]-1H-pyrimidine-2,4-dione
• InChI: InChI=1S/C18H23N3O3/c1-12-4-3-5-16(13(12)2)24-15-6-8-21(9-7-15)11-14-10-17(22)20-18(23)19-14/h3-5,10,15H,6-9,11H2,1-2H3,(H2,19,20,22,23)
• InChIKey: AZOFJHATIPDIER-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)OC2CCN(CC2)CC3=CC(=O)NC(=O)N3)C

GSK-2556286（Cat No.:I028347）is an investigational compound developed by GlaxoSmithKline, primarily studied for its potential in treating infections caused by Mycobacterium tuberculosis (Mtb), including drug-resistant strains. This compound targets a specific enzyme crucial for Mtb survival, exhibiting bactericidal activity that disrupts bacterial metabolism and replication. GSK-2556286 has shown promise in preclinical studies for its efficacy and selectivity, aiming to address the growing challenge of tuberculosis treatment resistance. Its development reflects ongoing efforts to introduce novel therapeutics for global health issues like tuberculosis, focusing on improving patient outcomes.